Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable
responses and prolonged survival in a variety of malignancies. Treatment is generally
well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune
thyroid dysfunction is among the most common irAE, but an assessment of the clinical,
mechanistic, and immunologic features has not been previously described.